Anaptysbio (ANAB) Operating Expenses (2016 - 2026)
Anaptysbio's (ANAB) quarterly Operating Expenses came in at $60.2 million in Q1 2026, up 8.83% YoY from $55.3 million in Q1 2025, and up 45.58% on a QoQ basis from $41.3 million in Q4 2025.
Anaptysbio (ANAB) Operating Expenses (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Operating Expenses data on file, last reported at $60.2 million in Q1 2026.
- Quarterly Operating Expenses rose 8.83% year-over-year to $60.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191.6 million (down 9.7% YoY) and the FY2025 annual result came in at $186.7 million, down 9.47% from the prior year.
- Operating Expenses rose to $60.2 million in Q1 2026, from $41.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $60.2 million in Q1 2026 to a low of $29.0 million in Q2 2022.
- A 5-year average of $44.7 million and a median of $45.8 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses soared 56.01% — and 2025, when it decreased 21.66%.
- Tracing ANAB's Operating Expenses over 5 years: stood at $32.8 million in 2022, then soared by 56.01% to $51.1 million in 2023, then rose by 3.21% to $52.8 million in 2024, then slipped by 21.66% to $41.3 million in 2025, then jumped by 45.58% to $60.2 million in 2026.
- The last three Operating Expenses figures came in at $60.2 million (Q1 2026), $41.3 million (Q4 2025), and $41.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 60.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.19 Mn |
| Dec 31, 2025 | 41.35 Mn |
| Sep 30, 2025 | 41.62 Mn |
| Jun 30, 2025 | 48.43 Mn |
| Mar 31, 2025 | 55.31 Mn |
| Dec 31, 2024 | 52.78 Mn |
| Sep 30, 2024 | 52.77 Mn |
| Jun 30, 2024 | 51.29 Mn |
| Mar 31, 2024 | 49.38 Mn |
| Dec 31, 2023 | 51.14 Mn |
| Sep 30, 2023 | 41.05 Mn |
| Jun 30, 2023 | 43.60 Mn |
| Mar 31, 2023 | 45.78 Mn |
| Dec 31, 2022 | 32.78 Mn |
| Sep 30, 2022 | 30.93 Mn |
| Jun 30, 2022 | 29.02 Mn |
| Mar 31, 2022 | 32.72 Mn |
| Dec 31, 2021 | 32.17 Mn |
| Sep 30, 2021 | 27.65 Mn |
| Jun 30, 2021 | 30.56 Mn |